Arecor Therapeutics plc
("Arecor" or the "Group")
PUBLICATION OF FULL YEAR FINANCIAL RESULTS DELAYED
Cambridge, UK, 3 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that, due to its auditor, Grant Thornton UK LLP, requiring additional time to complete its standard procedures, the Group's final results for the year ended 31 December 2023 will not be published on 7 May 2024, the previously planned date.
The Group will now announce its results in the week commencing 13 May 2024.
-ENDS-
For more information, please contact:
| Arecor Therapeutics plc | |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: info@arecor.com |
| | |
| Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: info@arecor.com |
| | |
| Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) | Tel: +44 (0) 20 7886 2500
|
|
WG Partners LLP (Financial Advisor) Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang
|
Tel: +44 (0) 203 705 9321 |
| ICR Consilium | |
| Chris Gardner, David Daley, Lindsey Neville | Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.